Business

Biotech, pharma, and money in science

Roche headquarters
Biotech

Roche buying Promedior for $390 million to develop drugs for fibrotic disease

By Jonathan Saltzman — Boston Globe

Vascepa pill handout
Biotech

An FDA panel backed Amarin’s fish oil drug. Here’s a detailed breakdown of the debate

By Adam Feuerstein and Matthew Herper

Charlie Baker
Politics

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

By Priyanka Dayal McCluskey — Boston Globe and Matt Stout — Boston Globe

Vascepa pill handout
Biotech

FDA documents point to a broadened approval for Amarin’s heart pill Vascepa

By Matthew Herper and Adam Feuerstein

Cambridge: Sarepta
Biotech

Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug

By Adam Feuerstein

Brain injury
Biotech

Startup Arkuda targets rapidly advancing, rare form of dementia

By Jonathan Saltzman — Boston Globe

Prescription conveyor belt
Pharmalot

If Trump were to place tariffs on Swiss drugs, U.S. patients are most likely to get hurt

By Ed Silverman

Dementia patients - China
Health

A new Alzheimer’s therapy is approved in China, delivering a surprise for the field but also questions

By Andrew Joseph

Business

Amgen acquires stake in BeiGene to expand cancer drug business to China

By Adam Feuerstein

Novartis International pharmaceutical
Biotech

Novartis’ Zolgensma gene therapy study halted by FDA on animal safety concerns

By Adam Feuerstein

Free flu shot clinic
Health

Seniors clamor for high-dose flu shot, but it’s not always easy to find

By Robert Weisman — Boston Globe

Adam's Take

Cel-Sci is publicly upbeat about its cancer drug. Privately it’s trying to sell stock

By Adam Feuerstein

Vertex Pharmaceuticals - sunset
Health

‘A game-changer’: How Vertex delivered on cystic fibrosis

By Adam Feuerstein and Matthew Herper

Business

Novartis gene therapy brings in $160 million, beating expectations

By Rebecca Robbins and Damian Garde

Business

This is awkward: Genome editing startup Beam has competition — from one of its own cofounders

By Adam Feuerstein and Damian Garde

Business

Drug distributors and Teva reach tentative settlement of opioids lawsuit

By Associated Press

Breast Cancer Cell - pink
Biotech

Seattle Genetics to seek approval for new breast cancer pill after positive clinical trial results

By Adam Feuerstein

Sean Parker
Biotech

Sean Parker, billionaire and philanthropist, gets an immunotherapy company off the ground

By Adam Feuerstein

DNA Strand - Abstract
Biotech

Blueprint and Ipsen to work together on treatment for ultra-rare genetic disorder

By Jonathan Saltzman — Boston Globe

Alexion Pharmaceuticals Inc
Biotech

Alexion acquiring Achillion to expand reach into rare, immune-related disease

By Adam Feuerstein

Test tubes and pipette
Biotech

UCB’s $2.5 billion purchase of Ra Pharma underscores immunology focus

By Jonathan Saltzman — Boston Globe

Biotech

Archived chat: An online discussion about the Q4 biotech scorecard

By Adam Feuerstein

colored DNA sequencing
Business

Illumina confronts the innovator’s dilemma

By Matthew Herper

Adam's Take

A cancer company has misled investors repeatedly about its drug. It’s time for some truth-telling

By Adam Feuerstein

Sarepta - Cambridge -AP
Biotech

Sarepta gene therapy improves muscle function for patients with rare limb-girdle disease

By Adam Feuerstein

Trump drug prices
Pharmalot

White House insists drug prices are falling, but critics say its report is flawed

By Ed Silverman

TUFTS - Sackler
Business

Top colleges took in at least $60 million from family that owns Purdue Pharma as opioid lawsuits piled up

By Associated Press

LabCentral Rendering
Biotech

Biotech incubator LabCentral to double its space in Boston

By Jonathan Saltzman — Boston Globe

Scorecard
Biotech

The biotech scorecard for the fourth quarter: 13 stock-moving events to watch

By Adam Feuerstein

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy